Many patients with type 2 diabetes will ultimately need

Size: px
Start display at page:

Download "Many patients with type 2 diabetes will ultimately need"

Transcription

1 SUPPLEMENT TO JAPI april 2011 VOL Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of long-term macrovascular and microvascular complications of type 2 diabetes and the associated morbidity and mortality. However majority of the patients do not achieve glycemic targets (HbA1c < 7%). Once insulin treatment has been initiated, each patient s regimen must be optimized and intensified to reach the target. In many guidelines, initial insulin therapy comprises a single dose of long-acting insulin or premixed insulin. Basal insulin will help to control fasting plasma glucose (FPG) level, but postprandial glucose excursions make a significant contribution to the overall daily hyperglycemia of type 2 diabetic patients. BIAsp 30 is the most prescribed analog premix and consequently has the largest evidence base in terms of randomized controlled trials (RCTs) and observational data. It follows that BIAsp 30 is therefore the analog premix most likely to be used for insulin intensification, both from basal insulin and from BIAsp 30 regimens: OD to BID and from BID to TID. Introduction Many patients with type 2 diabetes will ultimately need insulin therapy to maintain their target for glycemic control. Tight glycemic control is central to reducing the risk of long-term macrovascular and microvascular complications of type 2 diabetes and the associated morbidity and mortality. 1 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), 2 as well as the recent British National Institute of Clinical Excellence (NICE) guidelines on type 2 diabetes 3 recommend the addition of insulin for people with poorly controlled type 2 diabetes who are already on maximum tolerated doses of metformin and sulphonylurea. NICE recommends that this is the preferred management plan in those that are markedly hyperglycemic. The Diabetes Control and Complications Trial (DCCT) showed that, in patients with type 1 diabetes, intensive treatment reduced the risk of complications compared with conventional management. When patients originally assigned to conventional management were later switched to standard (presumably more intensive) management, they achieved similar standards of glycemic control, but their risk of microvascular and macrovascular complications remained raised. Similar findings have been reported after 10-year follow-up in UKPDS. The higher risk acquired initially due to poor glycemic control may not be easily overcome in the later improvements in glycemic control. Early control of hyperglycemia reduces the risk factor in developing long-term complication. The oxidative stress production secondary to hyperglycemia is believed to be the reason for this diabetic memory or legacy effect. This induces the production of superoxides by mitochondria leading to many diabetes-related complications. Therefore, it is very important to have good glycemic control as early as possible. This challenge is especially great for primary care physicians, who are increasingly responsible for the care of persons with diabetes. In many guidelines, initial insulin therapy comprises a single dose of long-acting insulin or premixed insulin. Basal insulin will help to control fasting plasma glucose (FPG) level, but postprandial glucose excursions make a significant contribution to the overall daily hyperglycemia of type 2 diabetic patients 4 where a single dose of premixed insulin is insufficient to reach the glycemic 1 Chief Diabetologist, Diabetes Care and Research Centre, G.C.I.B, Kankerbagh, Patna, , India; 2 Consultant Endocrinologist, Bharti Hospital, Vazeer chand Colony, Kunjapura Road, Karnal, , India targets. Forty-three percent of patients do not achieve glycemic targets (HbA1c < 7%). 5 Once insulin treatment has been initiated, each patient s regimen must be optimized and intensified to reach the target. Barriers to Insulin Initiation Many patients are highly restrained about commencing insulin therapy due to their prior perceptions about injection pain, inherent risks for hypoglycemia, weight gain, and/ or treatment complexity. 6 Other patients regard the need to begin insulin as a sign of impending disability, or as a sign of personal failure in their disease management or coping ability; some even view it as a sign that they have let down their family and healthcare providers. 7 Many studies have demonstrated hesitance by patients to accept insulin treatment. In the UKPDS study, 27% of patients initially declined insulin and a survey of 708 insulin-naïve patients found that 28% said they would be unwilling to take insulin if it was prescribed. 8 There are several myths, misperceptions, and negative attitude that act as barriers about the use of insulin among people with type 2 diabetes as follows: Insulin causes blindness, renal failure, amputations, heart attacks, strokes, or early death, Sense of personal failure Low self-confidence Low confidence in therapy Injection phobia Hypoglycemia concerns Feeling that diabetes is a serious cause of concern Negative impact on social life and job Inadequate health literacy, Health care provider inadequately explaining risks/benefits Limited insulin self-management training Some of the physicians barriers to timely initiate insulin are as follows: Concerns over patients with comorbidities Excess weight gain in already overweight patients Concerns about patient non-compliance Risk of severe hypoglycemia/adverse effects on QoL

2 18 SUPPLEMENT TO JAPI april 2011 VOL. 59 Lack of resources drug costs, staff, skills Patient refusal Initiating Insulin therapy After deciding to initiate insulin therapy, choices must be made about the insulin regimen to be prescribed and the exact goals of treatment. These decisions depend greatly on individual patients situations and aspirations. There are various choices of regimen when it comes to initiating insulin in type 2 diabetes. Each has its pros and cons. The simplest option is to add a oncedaily injection of a basal insulin formulation to the patient s existing oral antidiabetic drug regimen. At the other extreme is basal-bolus therapy where, in addition to basal insulin, the patient injects a rapid-acting bolus insulin before each meal, with each dose tailored to the anticipated carbohydrate intake. Basal-bolus therapy is the most sophisticated and physiologic approach, but it may be considered unnecessarily complicated and taxing for the patient with type 2 diabetes initiating insulin. A more popular choice is to use a premixed insulin formulation in which rapid- and long-acting components are included in the same vial or pen. Premixed insulins address the endogenous deficits in prandial as well as basal insulin secretion while minimizing injections and blood glucose monitoring. Initiating Insulin with Basal Analogs or Intensification with Basal-bolus The basal-bolus insulin strategy, which can be used in patients with either type 1 or type 2 diabetes, incorporates the concept of providing continuous basal insulin secretion throughout the day and night with brief increases in insulin levels at the time of meal ingestion through the administration of bolus doses. The use of preprandial regular insulin with bedtime NPH insulin as the basal insulin has been a common strategy for intensive insulin therapy in India. However, since regular insulin should be administered 20 to 40 min before a meal, a risk of hypoglycemia exists if the meal is delayed. If regular insulin is given just before a meal, high postprandial glucose levels and delayed hypoglycemia may result. A strategy that provides flexibility in the mealtime administration of insulin is the use of the rapid-acting insulin analogs like insulin aspart, administered immediately before meals, and a long-acting insulin, such as insulin detemir or glargine, as the basal insulin. NPH insulin, which exhibits peak action 5 to 7 h after administration, has also been used in combination with rapid-acting insulin analogs, commonly given twice daily. In patients with type 2 diabetes, twice-daily regimens of insulin mixtures provide similar glycemic control as an intense regimen of multiple daily injections. 9 Split self-mixed insulin regimens are effective for helping patients achieve glycemic control, yet an inherent risk of error exists. By combining the insulins themselves, patients can encounter problems with mixing technique and inaccurate dosing ratios, potentially reducing the effectiveness of the short-acting insulin. The benefits of premixed insulin formulations, such as a human insulin 70/30 mixed suspension (70% NPH insulin and 30% regular insulin), or NovoMix 30 (BIAsp 30) include reduced errors and improved dosing accuracy as well as the convenience of using a single vial. Initiation and Intensification of Insulin Therapy using Premix Insulins At present, international recommendations for intensification of insulin therapy using premix analogues are limited. The American Association of Clinical Endocrinologists (AACE 2007) guidelines cover the following: Transition from a long-acting insulin analogue to a premixed insulin analogue BID. Transition from an OD premixed insulin analog to a BID premixed insulin analog. In both scenarios, the recommendations are as follows: Divide the total daily dose into 2 equal doses (following 1:1 dose transfer from basal insulin) Give half before breakfast, the other half before dinner Titrate to goal based on self-monitored blood glucose data and diet history The largest meal will require a larger proportion of insulin Reduce the total dose by 20% if the patient experiences recurrent hypoglycemia. The AACE guidelines thus do not cover the possible intensification from BID premix analog to TID premix analog. The International Diabetes Federation (IDF 2009) guidelines mention premixes as viable intensification options but offer no specific guidance. The BIAsp 30 EU label has the indication for progressing from OD to BID and from BID to TID, but again no specific dosing guidelines are given for intensification. A recent consensus statement from the UK recommended premix analogs BID (intensifying to TID as required) as a treatment option for patients with type 2 diabetes switching from basal insulin. 10 The initial dose was recommended to be 80% of the final basal dose with titration to target over 14 days. However, these guidelines fail to include guidance on how the dose should be split and titrated. 10 New international guidelines that cover all appropriate scenarios for insulin intensification with premixed analogs are therefore needed. BIAsp 30 is the most prescribed analog premix and consequently has the largest evidence base in terms of randomized controlled trials (RCTs) and observational data. It follows that BIAsp 30 is therefore the analog premix most likely to be used for insulin intensification, both from basal insulin and from BIAsp 30 regimens: OD to BID and from BID to TID. Clinical Evidence for Intensification with BIAsp 30 Patients who need insulin intensification can be classified as the following 2 categories. 1. Those who fail to maintain good glycemic control even after using basal insulin±oads 2. Those who fail to maintain good glycemic control even after using BIAsp 30 OD or BID Clinical Evidence for Patients Failing on Basal Insulin Twice-daily regimen of BIAsp 30 has been shown to provide greater postprandial glycemic control than twice-daily NPH or BHI 30, or once-daily IGlarg. In a randomized double blind trial by Christiansen et al., 11 comparing 403 patients with type 2 diabetes, insufficiently controlled on OADs or NPH insulin, the mean prandial glucose in patients previously treated with NPH monotherapy was 1.05 mmol/l lower for the BIAsp 30 group, compared with those on NPH (p < ). These patients (coming from NPH monotherapy) also achieved a greater reduction in HbA1c when treated with twice-daily BIAsp 30, than when given

3 SUPPLEMENT TO JAPI april 2011 VOL twice-daily NPH (-0.78% vs -0.58%, respectively; p = 0.03). Boehm et al. 12 compared postprandial and overall glycemic control in a population of patients with type I or type II diabetes (n = 294) treated with BIAsp 30 or human insulin 30 in a randomized, open label parallel group study. The study was initially planned for 12 weeks then serially extended for 1, 2, and 4 years. 12,13 The HbA1c-lowering effect of BIAsp 30 is equal to that of BHI 30 (twice-daily in patients with type 1 or type 2 diabetes) but treatment with BIAsp 30 resulted in a more favourable degree of postprandial blood glucose control than BHI 30. After completion of a 3-month trial, the study patients with type 2 diabetes (n = 125) were allowed to continue treatment in an open-label fashion for an additional 21 months. There was no significant difference in HbA1c values between the two treatment groups but increment in body weight was only 0.5 kg in patients treated with BIAsp 30 as compared to 2 kg in BHI 30 (p = 0.07). 10 Raskin et al. 14 (INITIATE study) compared twice-daily BIAsp 30 with once-daily IGlarg in insulin-naïve patients with type 2 diabetes who were poorly controlled on OADs (only continuation with pioglitazone was allowed during the treatment phase). At the 28-week endpoint, the BIAsp 30 group had a lower mean HbA 1 C value than the IGlarg group (6.91% ± 1.17 vs. 7.41% ± 1.24; p < 0.01), and 66% of patients using BIAsp 30 reached the target HbA1c of <7% (from ~9.8% at the start of the study) compared with 40% of patients on IGlarg (p < 0.001). Kilo et al. 15 evaluated the clinical effectiveness of starting patients on a relatively simple regimen of once-daily injections of either biphasic insulin aspart 70/30 (10 min before dinner), NPH insulin (at 10 p.m.), or biphasic human insulin 70/30 (30 min before dinner) in combination with metformin. HbA 1 C was decreased by 2.3%, 1.9%, and 1.8% from baseline after treatment with BIAsp 70/30, NPH insulin, or human insulin 70/30, respectively. One RCT, the PREFER study, randomized 719 patients previously treated with 2 OADs with, or 1 without, basal insulin to either BIAsp 30 BID or basal bolus therapy (insulin detemir and insulin aspart). 16 After 26 weeks of therapy, patients previously treated with basal insulin showed a reduction in HbA 1 C of 0.75% (baseline level for the BIAsp 30 group was 8.40%). Although previous basal insulin dose was not reported, the total daily BIAsp 30 dose increased by 0.16 U/kg (from 0.47 to 0.63 U/kg) from week 3 to week 26, with a 50/50 breakfast/ dinner dose split. 16 In the largest observational study to date of BIAsp 30 in routine care, IMPROVE TM, patients who were switched from basal insulin to BIAsp 30 were, again, in poor glycemic control. Mean HbA 1 C was over 9.0% and patients had been diagnosed with type 2 diabetes, on average, more than 11 years previously. 17 After 26 weeks of BIAsp 30 therapy, reductions in HbA 1 C were) 1.64% in patients previously on human basal insulin, and) 1.83% in those previously on analogue basal insulin. When switching to BIAsp 30, the transfer of dose was 1:1.2 on average ( U/kg), but patients previously on OD basal insulin were started on a lower BIAsp 30 dose than those previously on BID basal insulin (0.36 and 0.44 U/kg, respectively). The majority of patients (82%) were transferred to a BID BIAsp 30 regimen, regardless of prior basal insulin injection frequency. The dose increase over the observation period was similar in both groups (0.14 vs U/kg) (24). To summarize, when BIAsp 30 BID was started following basal insulin therapy in routine care, the dose was transferred either 1:1 (if human basal) or 1:1.3 (if analog basal), without any safety concerns and resulted in improved glycemic control. When switching from OD basal insulin, the starting BIAsp 30 dose was smaller than when switching from BID basal insulin, giving an average dose transfer of 1:1.2. In addition, data from RCTs have shown that BID BIAsp 30 administration resulted in a 50:50 breakfast/dinner dose distribution. In the Physicians Routine Evaluation of Safety and Efficacy of BIAsp 30 Therapy (PRESENT) study, 18 which was a 6-month observational study in 15 countries, in which patients previously receiving long-acting analog insulin (n = 348), or human basal insulin (long and intermediate acting) (n = 3414), were transferred to BIAsp 30, HbA1c was significantly lowered in both groups (-1.60% and -1.42% in the basal analog and human basal groups; p < compared with baseline). Reductions in FPG and PPG were also statistically significant in both groups. The rate (events/patient/year) of overall hypoglycemia remained relatively constant in patients switching from basal analog group, but it was statistically lower in patients switching from human basal group (change from baseline -3.8; p < 0.001). In terms of dosing, prestudy basal insulin doses were 0.46 for human and 0.34 U/kg for analogue. When the switch to BIAsp 30 was made, doses were transferred, on average, approximately 1:1 for those coming from human basal (mean total baseline BIAsp 30 dose: 0.50 U/kg) and 1:1.3 for those coming from analog basal (mean total baseline BIAsp 30 dose: 0.45 U/kg). During the 6-month observation period, doses underwent very little titration, final doses were 0.56 and 0.48 U/kg, respectively. A large observational study (1-2-3 study), 19 in patients with type 2 diabetes failing oral agent therapy with or without basal insulin was conducted to assess whether addition and self-titration of biphasic insulin aspart 70/30 (BIAsp 30) could achieve American Association of Clinical Endocrinologists (AACE)/International Diabetes Federation (IDF) and American Diabetes Association (ADA) glycemic targets (HbA 1 C <6.5 and <7%). Enrolled patients (N = 100, HbA1c 7.5 and 10%) were >18 years of age, had diabetes >12 months and had received a stable antidiabetic regimen for at least 3 months [minimum of 2 oral antidiabetic drugs (OADs) or at least 1 OAD plus oncedaily basal insulin 60 U]. Patients discontinued prior basal insulin and added one injection of BIAsp. Patients self titrated their BIAsp 30 dose with investigator guidance every 3 or 4 days to achieve pre-breakfast fasting blood glucose (FBG) of mg/dl. At 16 weeks, a pre-breakfast injection of 6 U of BIAsp 30 was added if week 15 HbA 1 C exceeded 6.5%; the added dose was titrated to achieve pre-dinner BG of mg/dl. After an additional 16 weeks, 3 U of pre-lunch BIAsp 30 was added if HbA 1 C exceeded 6.5%. This added dose was adjusted based on 2-h post lunch BG to achieve postprandial glucose of mg/dl. Subjects achieving an HbA 1 C 6.5% at 15 and 31 weeks completed the study at weeks 16 and 32 respectively. At the end of the study period, in poorly-controlled type 2 diabetic patients the addition of once-daily BIAsp 30 at dinnertime resulted in 41% of the patient reaching HbA 1 C 7.0%. Addition of a 2nd and 3rd injection of BIAsp 30 resulted in a total of 70% and 77% of patients achieving an HbA 1 C of 7.0% respectively. This stepwise approach to insulin initiation and intensification achieved significant reductions in HbA 1 C, FPG, and PPG with no nocturnal hypoglycaemia and very few major hypoglycemic episodes. 19 In another 26 weeks, open-labeled, randomized parallel group, multinational treat-to-target RCT (Once Mix Study), insulin naïve subjects were randomized to receive either BIAsp 30 before dinner or insulin glargine at bedtime, both in

4 20 SUPPLEMENT TO JAPI april 2011 VOL. 59 combination with metformin and glimepiride. Estimated mean reduction in HbA 1 C from baseline to end of treatment was -1.41% with BIAsp 30 and -1.25% with insulin glargine (BIAsp 30 insulin glargine = -0.16%, 95% CI [-0.30; -0.02], p = 0.029). At the end of treatment, mean HbA 1 C was 7.1% and 7.3% for BIAsp 30 and insulin glargine, respectively. Significantly lower plasma glucose levels were observed with BIAsp 30 post-dinner (BIAsp 30 insulin glargine = mmol/l, 95% CI [-1.02; -0.03], p = 0.04) and at bedtime (BIAsp 30 insulin glargine = mmol/l, 95% CI [-1.25; -0.31], p < 0.01). The relative risk (RR) of experiencing a nocturnal hypoglycemic episode (00: a.m.) was significantly higher with BIAsp 30 than with insulin glargine (1.1 versus 0.5 episodes/year, RR = 2.41, 95% CI [1.34; 4.34], p = 0.003), but overall hypoglycemia rates were low. Clinical Evidence for Patients Failing on BIAsp 30 OD or BID Velojic-Golubovic et al. 21 in a 3-month study, compared the effect of adding biphasic insulin aspart 30 (BIAsp30) and premixed human insulin 30/70 (BHI30) along with metformin (met) on overall glycemic control in insulin-naïve, obese patients (30 males/20 females) with Type 2 diabetes (T2DM). The patients received either twice-daily BIAsp30 (N = 20) or twice-daily BHI30 (N = 30), and continued to receive maximal doses (2000 mg) of met for the duration of the study. Sulphonylureas were not administered as oral form of therapy. The primary efficacy endpoint was the change in HbA 1 C in both groups at the end of the study. The endpoints for safety were hypoglycemic episodes and weight gain. There was reduction in HbA 1 C in both the treatment groups at the end of the study (BIAsp30+MET by 2.5% [ %; 95% CI]; BHI30+MET by 1.18% ( %; 95% CI). Significantly better HbA1c reduction was seen with BIAsp30+MET (1.33%; p < 0.05) when compared to the BHI30+MET treatment arm. Better reduction in postprandial glucose and the fasting plasma glucose levels were also seen in the BIAsp30+MET. Similarly, weight gain was also lower in the BIAsp30+MET group. No significant difference in the frequency or number of hypoglycemic episodes was observed between the two groups. It was therefore concluded that adding BIAsp30 to met in obese patients with T2DM results in better glycemic control and less weight gain than adding BHI30. Yang et al. 22 conducted a study to assess the efficacy and safety of twice- and thrice-daily biphasic insulin aspart 30 (BIAsp 30) in Chinese subjects with type 2 diabetes inadequately controlled with oral antidiabetes drugs (OADs). In this 24-week, multicenter, parallel group, randomized, treat-to-target study, 321 Chinese insulin-naïve subjects with poorly controlled type 2 diabetes (fasting blood glucose, 7.8 mmol/l and A 1 C, 7.5%) were randomized (1:1) to twice- or thrice-daily (BID and TID groups, respectively) BIAsp 30 without OADs. Initial insulin doses were based on fasting blood glucose at randomization. Insulin dose was adjusted with algorithm-controlled titration to achieve premeal blood glucose of mmol/l. A 1 C decreased significantly in both groups (BID group to %; TID group to -0.07%). Thrice-daily BIAsp 30 showed superiority in A 1 C improvement (-0.33% [95% CI to -0.13]; p< 0.01) and helped more subjects achieve A 1 C targets -7% (BID group 51.3% vs. TID group 65.8%; P < 0.01). Thrice-daily BIAsp 30 was more effective in subjects with baseline A1C 9% (<7%: BID group 41.5% vs. TID group 58.3%; P < 0.01). There was no significant difference in rates of overall and nocturnal major and minor hypoglycemia per subject year between groups. No significant differences in weight gain (BID group 3.87 ± 0.28 kg; TID group 4.09 ± 0.27 kg) and mean daily insulin doses (BID group 0.82 ± 0.28 units/kg; TID group 0.86 ± 0.34 units/kg) were observed. It is concluded that twice- and thrice-daily BIAsp 30 were effective in insulin-naïve subjects with poorly controlled type 2 diabetes. Thrice-daily BIAsp 30 offered greater reduction in A 1 C without increasing risk of hypoglycemia, insulin dose, and weight gain, especially in subjects with A 1 C 9%. Ushakova et al. 23 evaluated the efficacy and safety profiles of 2 different regimens of BIAsp 30 compared with a regimen consisting of oral antidiabetic drugs (OADs) alone. The study enrolled 308 insulin-naïve patients with type 2 diabetes. Patients were randomized to receive BIAsp 30 TID, BIAsp 30 BID+MET, or continuation of their current OAD therapy for 16 weeks. Both BIAsp 30 TID and BIAsp 30 BID±MET were associated with significantly greater mean (SD) reductions in HbA1c relative to OADs alone (absolute percent reduction: 2.9% [1.5%], 3.0% [1.6%], and 2.1% [1.4%], respectively; P < 0.001, both insulin groups vs. OAD group) and improved postprandial glucose control (reduction in mean postprandial glucose: [4.07], [4.70], and 3.59 [4.22] mmol/l; P < 0.001, both insulin groups vs. OAD group). There were no significant differences in the mean frequency of overall hypoglycemic episodes between BIAsp 30 TID and BIAsp 30 BID+MET. Bebakar et al., 10 randomized 192 type 2 diabetic patients in a 2:1 ratio either to receive BIAsp30 or OAD only. Subjects randomized to BIAsp30 treatment received BIAsp30 once daily (o.d.) at dinnertime between Week 2 and Week 14, and those not reaching treatment targets were switched to twice daily (b.i.d.) BIAsp30 at Week 14. Significantly greater reductions in HbA1c was found with BIAsp30 (o.d.) vs. OAD-only treatment (1.16 vs. 0.58%; p < 0.001), with BIAsp30 (o.d.) and BIAsp30 (BID) treatments vs. OAD only treatment (1.24 vs vs. 0.67%; p < 0.01) over 26 weeks of therapy. Therefore, it may be appropriate to commence with one injection at dinnertime (or the largest meal) and add additional injections i.e. intensify therapy to twice and thrice daily. Tibaldi J 24 conducted a study to determine whether the addition of a third injection of biphasic insulin aspart 70/30 (BIAsp 30) just before lunch in older patients with type 2 diabetes who did not achieve goals with a twice-daily (BID) regimen would optimize glycemic control in a clinical practice setting. A retrospective chart analysis was conducted. In 12 patients aged years with type 2 diabetes that had been diagnosed between 5 and 24 years earlier and who remained on oral antidiabetes agents, a third injection of BIAsp 30 was added because optimal glycemic control (glycosylated hemoglobin [HbA1c] <7%) was not achieved on a BID regimen. Changes in HbA1c, body weight, total insulin dose, and frequency of hypoglycemia were analyzed after 6 months of three times daily (TID) treatment. Mean HbA1c decreased from 8.4% to 7.2%. An HbA1c goal of <7% was attained by 58% of patients. Although the total insulin dose increased by 11% with the TID regimen, pre-breakfast and predinner doses decreased by 15%. No patient experienced major hypoglycemia on BID or TID dosing. With the TID regimen, no minor hypoglycemic events were reported by patients and mean body weight decreased by 2.25 lb. The addition of a third injection of BIAsp 30 substantially improved HbA1c and decreased body weight and the incidence of hypoglycemia in 12 patients with type 2 diabetes who did not achieve optimal glycemic control on a BID regimen.

5 SUPPLEMENT TO JAPI april 2011 VOL Basal insulin OD or BID Premix OD (pre-dinner) or premix BID HbA1c 7-8% HbA1c>8% FPG +-pre-dinner BG: 4 6 mmol/l ( mg/dl) FPG +-pre-dinner BG > 6mmol/L (110 mg/dl) FPG>110 mg/dl FPG: mg/dl Titrate basal insulin to achieve FPG<110 mg/dl Switch to BIAsp 30 BID HbA 1c >7.0% Titrate premix OD or BID to achieve FPG +-pre-dinner BG <6 mmol/l (110 mg/dl) Fig. 1 : A simple algorithm for the intensification of basal insulin therapy once daily (OD) or twice daily (BID) (analogue or human) to biphasic insulin aspart 30/70 (BIAsp 30) BID. FPG, fasting plasma glucose (Unnikrishnan et al 2009). Conclusion from Clinical Data Regarding Intensification with BIAsp 30 In treat-to-target intensification studies the total dose of BIAsp 30 increased considerably in the consecutive intensification (OD-BID-TID) phases When BIAsp 30 BID was compared with BIAsp 30 TID in parallel-group studies, total dose did not differ that much Dose distribution of twice-daily administration was close to 50:50 In the majority of studies, the highest dose of BIAsp 30 TID was given at dinner followed by the doses at breakfast and lunch Practical Guidelines for Intensification of Insulin with BIAsp 30 Switching from basal insulin to OD or BID BIAsp 30 Unnikrishnan et al. 25 has provided an algorithm to switch from basal to premix insulin (BIAsp 30) (Fig. 1). If the patient has HbA1c higher than 8%, they should be transferred to BIAsp 30 BID. If HbA 1 C is moderately elevated (between 7.0% and 8.0%) but FPG is within the normal range (4 6 mmol/l), the suboptimal overall glycemia is probably caused by elevated PPG; thus, the patient should be transferred to BIAsp 30 BID as it provides prandial coverage as well. If, however, HbA 1 C is between 7.0% and 8.0%, and FPG is higher than 6 mmol/l, the existing basal insulin dose(s) can be titrated further until the patient achieves FPG below 6 mmol/l. If recurrent hypoglycaemia limits uptitration of the basal dose, or the daily dose reaches 0.5 U/kg (insulin units per kg body weight), switching to BIAsp 30 BID can be considered. Intensification with Premix Insulin The following recommendations can be followed when intensifying premix insulin therapy. OD to BID Split the OD dose into equal breakfast and dinner doses (50:50) Titrate the doses preferably once a week according to the algorithm below Discontinue SUs Continue metformin Consider discontinuing thiazolidinediones (TZDs) as per local guidelines and practice Switch to premix BID or TID Fig. 2 : A simple algorithm for intensifying therapy from biphasic insulin aspart 30/70 (BIAsp 30) once (OD) or twice daily (BID) to BIAsp 30 twice or three-times daily (TID). FPG, fasting plasma glucose; BG, blood glucose Administer BIAsp 30 just before meals If hypoglycaemia* occurs BID to TID Add 2 6 U or 10% of total daily BIAsp 30 dose before lunch Down titration of morning dose (-2 to 4 U) may be needed after adding the lunch dose Titrate the doses preferably once a week according to the algorithm below Continue metformin Consider discontinuing thiazolidinediones (TZDs) as per local guidelines and practice Administer BIAsp 30 just before meals A simple algorithm for intensifying with analogue premix is given below. Titration Algorithm for Implementing the Above Guidelines Pre-prandial BG value Dose change <4.4 mmol/l <80 mg/dl 2U mmol/l mg/dl mmol/l mg/dl +2U mmol/l mg/dl +4U >10.0 mmol/l >180 mg/dl +6U Ref: Unnikrishnan et al (25) When using this titration algorithm to adjust BIAsp 30 doses after intensifying basal insulin therapy to BIAsp 30 BID, or intensifying BIAsp 30 OD or BID to BIAsp 30 BID or TID, the following guidance should be noted: The lowest of 3 previous days premeal levels should be used. Always change the mealtime dose preceding the measurement. The dose should not be increased if hypoglycemia occurs during these days. Dose adjustments can be made once a week until target is reached. Only one dose at a time should be changed: the evening dose should be titrated first, followed by the breakfast dose and finally the lunch dose as appropriate.

6 22 SUPPLEMENT TO JAPI april 2011 VOL. 59 Clinical Insights to be Considered During BIAsp 30 Dosing and Titration Patients with high BMI likely to require higher doses More care when titrating thin/elderly (more insulin sensitive) patients Multiple doses of insulin easier to administer using pens Give some dosing expectations (use examples of typical insulin dose ranges in the text but not in the algorithm) Explaining the rationale behind using more insulin injections is a safer way of administering a higher insulin dose. References 1. UK Prospective Diabetes Study (UKPDS), Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: Nathan DM, Buse JB, and Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;28: NICE Type 2 Diabetes newer agents NICE Clinical Guideline 87 (CG 87). NICE, London, Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003;26: Ford ES, Li C, Little RR, Mokdad A. Trends in A1C Concentrations Among U.S. Adults With Diagnosed Diabetes From 1999 to Diabetes Care 2008;31: Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26Suppl3:S18-S Peyrot M, Rubin RR, Lauritzen T et al. For the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28: Polonsky WH, Fisher L, Guzman S et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28: Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114: Bebakar WMW, Chow CC, Kadir KA. On behalf of the BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007;9: Christiansen JS, Vaz J, Metelko et al. Twice daily biphasic insulin aspart improves postprandial glycemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003;5: Boehm BO, Vaz JA, Brondsted L et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15: Boehm B, Home P, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19: Raskin P, Allen E, Hollander P, et al. for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28: Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17: Liebl A, Prager R, Binz K et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11: Gumprecht J, Benroubi M, Borzi V et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009;63: Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study Int J Clin Pract 2008;62: Strojek K, Bebakar AMW, Khutsoane DT, Pesic M, Sˇ mahelova, Sˇ mahelova, Thomsen HF, Kalra S. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Current Medical Research Opinion 2009;25: Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest 2009;32: Yang w,ji Q,ZHu D,Yang J, Chen L, Liu Z,Yu D, Yan L. Biphasic insulin Aspart 30 three times daily is more effective than a twicedaily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008;31: Ushakova O, Sokolovskaya V, Morozova A et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clinical Therapeutics 2007; Tibaldi JT. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycaemic control on a twice-daily regimen: A retrospective case series analysis from clinical practice. Advances in Therapies 2007;24: Unnikrishnan AG, Tibaldi J, Hadley-brown M, Krentz A, Ligthelm R, Damci T, Gumprecht J, Gero L, Mu Y, Raz I. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009;11: IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, www. idf.org/webdata/docs/idf%20ggt2d.pdf (accessed June 2009).

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2 Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick

More information

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย

More information

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step

More information

Algorithms for Glycemic Management of Type 2 Diabetes

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

Workshop A Tara Kadis

Workshop A Tara Kadis Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system

More information

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by

More information

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of

More information

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL 464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT

More information

Intensifying Insulin Therapy

Intensifying Insulin Therapy Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning

More information

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl

More information

TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES

TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin

More information

Insulin initiation in type 2

Insulin initiation in type 2 Earn 3 CPD Points online Insulin initiation in type 2 diabetes This text is derived from the insulin initiation video presentation by Dr Ted Wu and includes all relevant references Dr Ted Wu Staff Specialist,

More information

Present and Future of Insulin Therapy: Research Rationale for New Insulins

Present and Future of Insulin Therapy: Research Rationale for New Insulins Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents

More information

Insulin Initiation and Intensification

Insulin Initiation and Intensification Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics

More information

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%

More information

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic

More information

Intensive Insulin Therapy in Diabetes Management

Intensive Insulin Therapy in Diabetes Management Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition

More information

INSULIN INTENSIFICATION: Taking Care to the Next Level

INSULIN INTENSIFICATION: Taking Care to the Next Level INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely

More information

Britni Hebert, MD PGY-1

Britni Hebert, MD PGY-1 Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising

More information

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval

More information

Diabetes: When To Treat With Insulin and Treatment Goals

Diabetes: When To Treat With Insulin and Treatment Goals Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy

More information

Type 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.

Type 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011. Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin

More information

When and how to start insulin: strategies for success in type 2 diabetes

When and how to start insulin: strategies for success in type 2 diabetes 1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology

More information

Type 2 diabetes mellitus

Type 2 diabetes mellitus Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,

More information

Insulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences

Insulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of

More information

Insulin initiation in type 2 diabetes: Experience and insights

Insulin initiation in type 2 diabetes: Experience and insights Insulin initiation in type 2 diabetes: Experience and insights Joan Everett A diagnosis of type 2 diabetes can be devastating for the individual and their family. Furthermore, many people with diabetes

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

The prevalence of type 2 diabetes

The prevalence of type 2 diabetes Insulin Therapy for Management of Type 2 Diabetes Mellitus: Strategies for Initiation and Long-term Patient Adherence Steven H. Barag, DO Effective glycemic control is essential to minimize the long-term

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Indian National Consensus Group: National Guidelines on Initiation and Intensification of Insulin Therapy with Premixed Insulin Analogs

Indian National Consensus Group: National Guidelines on Initiation and Intensification of Insulin Therapy with Premixed Insulin Analogs 51 Chapter Indian National Consensus Group: National Guidelines on Initiation and Intensification of Insulin Therapy with Premixed Insulin Analogs Ashok Kumar Das, Binode Kumar Sahay, V Seshiah, V Mohan,

More information

The first injection of insulin was given on

The first injection of insulin was given on EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

Global Guideline for Type 2 Diabetes

Global Guideline for Type 2 Diabetes INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication

More information

Presented By: Dr. Nadira Husein

Presented By: Dr. Nadira Husein Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,

More information

Everyday Practice: Diabetes Mellitus

Everyday Practice: Diabetes Mellitus THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India

More information

Starting Insulin Sooner Than Later

Starting Insulin Sooner Than Later Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration

More information

Shanmugasundar G., Anil Bhansali, Rama Walia, Pinaki Dutta & Vimal Upreti

Shanmugasundar G., Anil Bhansali, Rama Walia, Pinaki Dutta & Vimal Upreti Indian J Med Res 135, January 2012, pp 78-83 Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus A

More information

Glycaemic Control in Adults with Type 1 Diabetes

Glycaemic Control in Adults with Type 1 Diabetes Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes

More information

User guide Basal-bolus Insulin Dosing Chart: Adult

User guide Basal-bolus Insulin Dosing Chart: Adult Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For

More information

Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB

Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow

More information

Are insulin analogs worth their cost in type 2 diabetes?

Are insulin analogs worth their cost in type 2 diabetes? Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology

More information

Diabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.

Diabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph. Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact

More information

Insulin myths and facts

Insulin myths and facts london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST

ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief

More information

Consensus Evidence-based Guidelines for Insulin Initiation, Optimization and Continuation in Type 2 Diabetes Mellitus

Consensus Evidence-based Guidelines for Insulin Initiation, Optimization and Continuation in Type 2 Diabetes Mellitus supplement to Journal of the association of physicians of india Published on 1st of every month 1st July, 2014 VOL. 62 49 Consensus Evidence-based Guidelines for Insulin Initiation, Optimization and Continuation

More information

Insulin Therapy for Optimizing Glycemic Control in Type 2 DM. Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013

Insulin Therapy for Optimizing Glycemic Control in Type 2 DM. Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013 Insulin Therapy for Optimizing Glycemic Control in Type 2 DM Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013 Case 1 A 45 years-old Thai female with T2DM for 3 years

More information

A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration

A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast

More information

How To Initiate Insulin

How To Initiate Insulin Initiation and Titration of Insulin Analogs in the Patient with Type 2 Diabetes Supported by an educational grant from Novo Nordisk Inc. This program is supported by an educational grant from Novo Nordisk

More information

A 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial)

A 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial) CLINICAL RESEARCH STUDY A 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial) David S. Oyer, MD, a Mark D. Shepherd, MD, b Franklin C. Coulter, MD, c Anuj

More information

Type 2 Diabetes - Pros and Cons of Insulin Administration

Type 2 Diabetes - Pros and Cons of Insulin Administration Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing

More information

Diabetes Medications: Insulin Therapy

Diabetes Medications: Insulin Therapy Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta

More information

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United

More information

Cochrane Quality and Productivity topics

Cochrane Quality and Productivity topics Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices

More information

Starting patients on the V-Go Disposable Insulin Delivery Device

Starting patients on the V-Go Disposable Insulin Delivery Device Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate

More information

Most patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?

Most patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles? ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)

More information

Initiating & titrating insulin & switching in General Practice Workshop 1

Initiating & titrating insulin & switching in General Practice Workshop 1 Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes

More information

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin

More information

Insulin/Diabetes Calculations

Insulin/Diabetes Calculations Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate

More information

Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives

Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,

More information

Starting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres

Starting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier

More information

Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy

Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2

More information

Insulin therapy in type 2 diabetes

Insulin therapy in type 2 diabetes Med Clin N Am 88 (2004) 865 895 Insulin therapy in type 2 diabetes Trent Davis, MD, Steven V. Edelman, MD* Section of Diabetes/Metabolism, Veterans Affairs San Diego HealthCare System, 3350 La Jolla Village

More information

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than

More information

Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient

Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient REVIEW ARTICLE Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient L. Meneghini doi: 10.1111/j.1742-1241.2008.01816.x SUMMARY Aims: To increase awareness

More information

Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives

Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,

More information

Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review)

Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review) Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review) Swinnen SG, Simon ACR, Holleman F, Hoekstra JB, DeVries JH This is a reprint of a Cochrane review, prepared and maintained

More information

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding

More information

Using Insulin in Type 2 Diabetes: In Need of a Renaissance? Introduction. David Kerr, M.D., and Tolulope Olateju, M.B., B.S.

Using Insulin in Type 2 Diabetes: In Need of a Renaissance? Introduction. David Kerr, M.D., and Tolulope Olateju, M.B., B.S. Journal of Diabetes Science and Technology Volume 5, Issue 4, July 2011 Diabetes Technology Society EDITORIAL Using Insulin in Type 2 Diabetes: In Need of a Renaissance? David, M.D., and Tolulope Olateju,

More information

Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis

Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis ORIGINAL ARTICLE JN EPHROL 25( DOI: 10.5301/jn.5000081 Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis Masao Toyoda, Moritsugu Kimura, Naoyuki

More information

Diabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)

Diabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult) Review Due Date: 2016 May PATIENT CARE ORDERS Weight (kg) Known Adverse Reactions or Intolerances DRUG No Yes (list) FOOD No Yes (list) LATEX No Yes ***See Suggestions for Management (on reverse)*** ***If

More information

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1) Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the

More information

Diabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)

Diabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing) Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics

More information

Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis

Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00934.x Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis E. Mannucci, M. Monami and N. Marchionni Department of

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

BIAsp30 A 1 chieve Tehran 31 July 2015

BIAsp30 A 1 chieve Tehran 31 July 2015 BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of

More information

Safety and Effectiveness of Modern Insulin Therapy: The Value of Insulin Analogs

Safety and Effectiveness of Modern Insulin Therapy: The Value of Insulin Analogs STEPHEN BRUNTON, MD Cabarrus Family Medicine Residency Program, Charlotte, NC Safety and Effectiveness of Modern Insulin Therapy: Dr Brunton is director of faculty development at the Cabarrus Family Medicine

More information

The U.K. Prospective Diabetes Study

The U.K. Prospective Diabetes Study Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Comparison of two treatment algorithms using insulin glargine

More information

Treatment Approaches to Diabetes

Treatment Approaches to Diabetes Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point

More information

Calculating Insulin Dose

Calculating Insulin Dose Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This

More information

Multiple-dose insulin injection therapy in patients with type 2 diabetes using a basal-bolus regimen, team management, and nutrition education

Multiple-dose insulin injection therapy in patients with type 2 diabetes using a basal-bolus regimen, team management, and nutrition education Multiple-dose insulin injection therapy in patients with type 2 diabetes using a basal-bolus regimen, team management, and nutrition education Alison Baldwin, BS University of South Carolina School of

More information

The U.K. Prospective Diabetes Study

The U.K. Prospective Diabetes Study Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Initiating Insulin Therapy in Type 2 Diabetes A comparison of biphasic and basal insulin analogs PHILIP RASKIN, MD 1 ELSIE ALLEN, MD 2 PRISCILLA

More information

Insulin therapy in various type 1 diabetes patients workshop

Insulin therapy in various type 1 diabetes patients workshop Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of

More information

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary

More information

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06 CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health

More information

INSULIN REGIMENS in type 2 diabetes

INSULIN REGIMENS in type 2 diabetes A review of INSULIN and INSULIN REGIMENS in type 2 diabetes a Joshi P, PhD, FRCP,FRS Med, FICA Joshi S, MBChB, MSc(Pharm) Med(UL) Diabetes Care Centre, Louis Pasteur Medical Centre, Pretoria a Emeritus

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

DM Management in Elderly- What are the glucose targets?

DM Management in Elderly- What are the glucose targets? DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures

More information

Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemir

Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemir Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Glargine to Detemir Ginelle A. Bryant, Pharm.D., Deanna L. McDanel, Pharm.D., Kathleen E. Horner, Pharm.D., Karen B. Farris,

More information

(30251) Insulin SQ Prandial Carbohydrate

(30251) Insulin SQ Prandial Carbohydrate Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered

More information

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of: Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus

More information

Intensifying Insulin In Type 2 Diabetes

Intensifying Insulin In Type 2 Diabetes Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant

More information

BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS

BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,

More information